2024-10-25 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**Company Overview:** Thermo Fisher Scientific Inc. is a global leader in serving science, offering a wide range of products and services for research, analytical instruments, laboratory supplies, and life sciences solutions.

**1. Performance Comparison:**

* **Cumulative Return (TMO):** 218.48%
* **Cumulative Return (VOO):** 135.48%
* **Return Difference:** 83.0
* **Relative Divergence:** 38.8%

TMO has outperformed the S&P 500 (VOO) by a significant margin, with a cumulative return almost 83% higher than the benchmark. This places TMO's performance at the 38.8th percentile compared to its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $557.38 (Post-market: $557.43)
* **5-day Moving Average:** $584.28
* **20-day Moving Average:** $598.05
* **60-day Moving Average:** $605.44

The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential downward trend in the short term. 

**3. Technical Indicators:**

* **RSI:** 27.86
* **PPO:** -0.61
* **Delta_Previous_Relative_Divergence:** -16.87 (-)
* **Expected Return:** 47.06%

The RSI suggests that the stock is currently in oversold territory. The negative PPO value also supports the potential for a further downward movement. The negative Delta_Previous_Relative_Divergence indicates a recent short-term decline in relative performance. However, the high Expected Return suggests a potential for long-term upside growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | 4.05 | $10.54 B |
| 2024-05-03 | 3.47 | $10.35 B |
| 2023-11-03 | 4.44 | $10.57 B |
| 2023-08-04 | 3.53 | $10.69 B |
| 2024-08-02 | 3.53 | $10.69 B |

The latest earnings report for the quarter ending 2024-08-02 showed an EPS of $4.05, exceeding analyst expectations. Revenue also came in higher than expected at $10.54 billion. Overall, the company's recent earnings have been consistently strong, demonstrating continued growth and profitability.

**5. News and Recent Issues:**

* **Recent Earnings Release:** TMO released its Q2 2024 earnings on August 2, 2024, reporting strong earnings and revenue growth. This positive news has been well-received by the market, contributing to a recent price surge.
* **Market Outlook:** The market outlook for TMO remains positive due to the company's strong financial performance, continued growth in various sectors, and potential for future expansion in emerging markets. 
* **Analyst Opinions:** Most analysts have a "Buy" or "Strong Buy" rating on TMO, citing its strong fundamentals and growth potential. 
* **Performance Highlights:** Recent performance highlights include continued market share gains, new product launches, and strategic acquisitions. This indicates the company's commitment to innovation and growth in the scientific and life sciences sectors.

**6. Overall Analysis:**

TMO has demonstrated strong performance, consistently exceeding the market benchmark and showing healthy growth in earnings and revenue. While the stock has experienced recent downward pressure, its long-term growth potential remains promising.  The company's strong financial performance, market leadership, and continued investment in research and development suggest a positive outlook for investors.

**7. Recommendations:**

Based on the above analysis, TMO appears to be a strong long-term investment option. Although the current stock price has experienced some downward movement, its historical performance, positive earnings, and robust market outlook suggest a potential for future growth.  Investors with a long-term horizon may consider adding TMO to their portfolio. 
